Victim: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea.
Incidents
- November 14, 2021: Supernus Pharma Hit in Ransomware Attack